Literature DB >> 2174666

Peripheral neuropathy associated with eosinophilia-myalgia syndrome.

T D Heiman-Patterson1, S J Bird, G J Parry, J Varga, M E Shy, N W Culligan, L Edelsohn, G T Tatarian, M P Heyes, C A Garcia.   

Abstract

In 1989, the Centers for Disease Control recognized the existence of an epidemic illness characterized by myalgia and eosinophilia in individuals taking preparations containing L-tryptophan. We evaluated 3 patients with eosinophilia-myalgia syndrome who presented with subacute progressive neuropathies. The neuropathies were predominantly motor and maximal in the lower extremities. Two patients were confined to a wheelchair and one was ventilator-dependent and bedridden. Sensory loss predominantly involved small fiber modalities. Electrophysiological studies showed multifocal marked conduction slowing and conduction block indicating segmental demyelination, with associated axonal degeneration that was accentuated distally. Examination of sural nerve biopsy specimens demonstrated axonal degeneration in all 3 patients and perivascular infiltrates in 2. Levels of quinolinic acid, a neurotoxic metabolite of L-tryptophan, were elevated in the cerebrospinal fluid in the 2 patients in whom it was measured. The cause of the neuropathy is unknown but may include immune mechanisms or toxicity of eosinophils, L-tryptophan, its metabolic products, or contaminants within L-tryptophan preparations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174666     DOI: 10.1002/ana.410280409

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

Review 1.  Tryptophan. Current status and future trends for oral administration.

Authors:  L D Kaufman; R M Philen
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

2.  A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

Authors:  R M Silver; A Ludwicka; M Hampton; T Ohba; S A Bingel; T Smith; R A Harley; J Maize; M P Heyes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 3.  Prevention and management of drug-induced peripheral neuropathy.

Authors:  L L Olesen; T S Jensen
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

4.  Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome.

Authors:  M L Freimer; J D Glass; V Chaudhry; W R Tyor; D R Cornblath; J W Griffin; R W Kuncl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

5.  A Case of Eosinophilia Myalgia Syndrome: Imaging Features of a Unique and Rare Entity.

Authors:  Marisa Yadav; Suresh Kumar; Anupam Jhobta; Sushma Makhaik
Journal:  Ann Indian Acad Neurol       Date:  2022-03-25       Impact factor: 1.714

6.  Pediatric sciatic neuropathy presenting as painful leg: A case report and review of literature.

Authors:  Manish Prasad; Mohamed Babiker; Ganesh Rao; Christopher Rittey
Journal:  J Pediatr Neurosci       Date:  2013-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.